Why the study?
Does revascularization (CABG) improve survival compared to modern medical therapy in patients with ischemic cardiomyopathy and HFrEF?
Does revascularization (CABG) improve survival compared to modern medical therapy in patients with ischemic cardiomyopathy and HFrEF?
Answers are grounded in this paper and cite their sources.
This review revisits the role of revascularization (CABG) in patients with ischemic cardiomyopathy and HFrEF in the context of modern medical therapy.
Ischemic cardiomyopathy (ICM) is a leading cause of heart failure, with rising incidence due to the increased prevalence of coronary artery disease. Patients with ICM have higher rates of heart failure with reduced left ventricular ejection fraction (HFrEF), hospitalization for acute heart failure, ventricular arrhythmias, and angina. International guidelines recommend coronary artery bypass graft (CABG) surgery in patients with stable ischemic heart disease and left ventricular ejection fraction (LVEF) <35% to improve survival irrespective of symptoms.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a review in Ischemic cardiomyopathy and heart failure with reduced ejection fraction. Revascularization (CABG) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: